Management of severe dyslipidaemia: Role of PCSK9 inhibitors

Stephen J. Nicholls

doi:10.15420/ecr.2018.3.2

Management of severe dyslipidaemia: Role of PCSK9 inhibitors

Stephen J. Nicholls

Research output: Contribution to journal › Article › Other › peer-review

1 Citation (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulation of LDL receptors on the hepatocyte surface and therefore is essential for effective removal of LDL particles from circulation. Genetic and biochemical studies have established that altered PCSK9 functionality influences both LDL cholesterol levels and cardiovascular risk. This has prompted development of inhibitory strategies targeting PCSK9. Study of monoclonal PCSK9 antibodies has progressed to the clinic, where they have been found to lower LDL cholesterol levels and reduce cardiovascular event rates in large, clinical outcome trials. The use of PCSK9 inhibitors in the setting of dyslipidaemia is reviewed.

Original language	English
Pages (from-to)	9-13
Number of pages	5
Journal	European Cardiology Review
Volume	13
Issue number	1
DOIs	https://doi.org/10.15420/ecr.2018.3.2
Publication status	Published - 1 Jun 2018
Externally published	Yes

Keywords

Atherosclerosis
Cardiovascular risk
Clinical trials
Lipids
Risk factors

Access to Document

10.15420/ecr.2018.3.2

Cite this

@article{c27a95bb9cef4004b1f21e6371230e6f,

title = "Management of severe dyslipidaemia: Role of PCSK9 inhibitors",

abstract = "Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulation of LDL receptors on the hepatocyte surface and therefore is essential for effective removal of LDL particles from circulation. Genetic and biochemical studies have established that altered PCSK9 functionality influences both LDL cholesterol levels and cardiovascular risk. This has prompted development of inhibitory strategies targeting PCSK9. Study of monoclonal PCSK9 antibodies has progressed to the clinic, where they have been found to lower LDL cholesterol levels and reduce cardiovascular event rates in large, clinical outcome trials. The use of PCSK9 inhibitors in the setting of dyslipidaemia is reviewed.",

keywords = "Atherosclerosis, Cardiovascular risk, Clinical trials, Lipids, Risk factors",

author = "Nicholls, {Stephen J.}",

year = "2018",

month = jun,

day = "1",

doi = "10.15420/ecr.2018.3.2",

language = "English",

volume = "13",

pages = "9--13",

journal = "European Cardiology Review",

issn = "1758-3756",

publisher = "Medical Media Communications LTD, T/A Radcliffe Cardiology",

number = "1",

}

TY - JOUR

T1 - Management of severe dyslipidaemia

T2 - Role of PCSK9 inhibitors

AU - Nicholls, Stephen J.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulation of LDL receptors on the hepatocyte surface and therefore is essential for effective removal of LDL particles from circulation. Genetic and biochemical studies have established that altered PCSK9 functionality influences both LDL cholesterol levels and cardiovascular risk. This has prompted development of inhibitory strategies targeting PCSK9. Study of monoclonal PCSK9 antibodies has progressed to the clinic, where they have been found to lower LDL cholesterol levels and reduce cardiovascular event rates in large, clinical outcome trials. The use of PCSK9 inhibitors in the setting of dyslipidaemia is reviewed.

AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulation of LDL receptors on the hepatocyte surface and therefore is essential for effective removal of LDL particles from circulation. Genetic and biochemical studies have established that altered PCSK9 functionality influences both LDL cholesterol levels and cardiovascular risk. This has prompted development of inhibitory strategies targeting PCSK9. Study of monoclonal PCSK9 antibodies has progressed to the clinic, where they have been found to lower LDL cholesterol levels and reduce cardiovascular event rates in large, clinical outcome trials. The use of PCSK9 inhibitors in the setting of dyslipidaemia is reviewed.

KW - Atherosclerosis

KW - Cardiovascular risk

KW - Clinical trials

KW - Lipids

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=85051765648&partnerID=8YFLogxK

U2 - 10.15420/ecr.2018.3.2

DO - 10.15420/ecr.2018.3.2

M3 - Article

AN - SCOPUS:85051765648

SN - 1758-3756

VL - 13

SP - 9

EP - 13

JO - European Cardiology Review

JF - European Cardiology Review

IS - 1

ER -

Management of severe dyslipidaemia: Role of PCSK9 inhibitors

Abstract

Keywords

Access to Document

Other files and links

Cite this